Enterprise Value
22.77M
Cash
201M
Avg Qtr Burn
-5.28M
Short % of Float
4.77%
Insider Ownership
35.14%
Institutional Own.
13.52%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Natrunix Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Data readout | |
Natrunix (XB2001) w/ ON+5FU+LV Details Cancer, Pancreatic cancer | Phase 1/2 Update | |
Hutrukin Details Brain disease, Ischemic stroke | Phase 1 Data readout | |
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer | Phase 1 Update | |
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa | Failed Discontinued | |
Bermekimab Details Skin disease/disorder | Failed Discontinued | |
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus | Failed Discontinued |